[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copd-chronic-obstructive-pulmonary-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copd-chronic-obstructive-pulmonary-disease":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,46,73,104,128,151,181,203,224,244,264,285,307,338,366,395,420,464,491,518,544,581,605,631,657],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100640105","the-study-of-chronic-obstructive-pulmonary-disease-copd-participants-treated-with-dupilumab-stride-registry-100640105",false,"NCT07612878","The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry","STRIDE","Inclusion Criteria:\n\n* COPD patients who are newly referred to start dupilumab treatment\n* Age ≥ 40 years\n* Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit\n\nExclusion Criteria:\n\n* Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)\n* Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments\n* Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial","ALL","40 Years",{"count":20,"type":21},350,"ESTIMATED","24 Months","OBSERVATIONAL","The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and\u002For severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.",[26],"COPD (Chronic Obstructive Pulmonary Disease)",[28,29,30,31,32,33],"COPD","Dupilumab","Dupixent","Chronic Obstructive Pulmonary Disease","Exacerbation","Home Spirometry","NOT_YET_RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":21},"2026-07-31",{"date":42,"type":21},"2029-11-30",{"name":44,"class":45},"Sanofi","INDUSTRY",{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100537910","phase-3-a-study-evaluating-the-efficacy-of-budesonide-glycopyrronium-and-formoterol-fumarate-metered-dosed-inhaler-on-cardiopulmonary-outcomes-in-chronic-obstructive-pulmonary-disease-100537910","NCT06283966","A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease","A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)","THARROS","Inclusion Criteria:\n\n1. Male or female participants must be 40 to 80 years of age inclusive, at the time of signing\n\n   the ICF.\n2. Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)\n3. A diagnosis of COPD confirmed by a post-bronchodilator FEV1\u002FFVC ratio \\\u003C 70%\n\n   at V1.\n4. Current or former smokers with a history of at least 10 pack-years of cigarette smoking;\n\n   defined as (number of cigarettes per day\u002F20) x number of years smoked. Previous smokers are defined as those who have stopped smoking for at least 6\n\n   months prior to V1.\n5. A baseline peripheral blood eosinophil count of ≥ 100 cells\u002Fmm3 assessed at Visit 1 by\n\n   the central laboratory\n6. A CAT score of ≥ 10 at Visit 1.\n7. Participant must fulfill at least 1 of the 4 CV disease\u002Frisk factor criteria below \\[(a), (b),\n\n   (c), or (d)\\]:\n   1. : Established CV Disease\n   2. : Combination of CV risk factors:\n\n      * Hypertension\n      * Diabetes Mellitus\n      * Chronic Kidney Disease\n      * Dyslipidemia\n      * Obesity\n   3. : High risk of CV disease determined using an established CV risk assessment\n\n      tool.\n   4. : CT coronary Artery Calcification\n8. Willing and, in the opinion of the investigator, able to adjust current COPD therapy, as\n\n   required by the protocol.\n9. Willing to visit at the study site or participate in virtual visits as required per the protocol\n\n   to complete all study assessments.\n10. A female is eligible to enter and participate in the study if the female is of:\n\n    * Non-childbearing potential: either permanently sterilized or who are post-menopausal.\n    * Childbearing potential: has a negative serum pregnancy test at V1 and must use one\n\n    highly effective form of birth control.\n11. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.\n\nExclusion Criteria:\n\n1. Active diagnosis of asthma within the past 5 years (previous diagnosis as a child or adolescent are eligible), asthma-COPD overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.\n2. End-stage renal disease requiring renal replacement therapy\n3. History of heart or lung transplant or actively listed for heart or lung transplant.\n4. Implanted left ventricular assist device or implant anticipated in \\\u003C 3 months.\n5. History of lung cancer and\u002For treatment for lung cancer within the 5 years prior to Visit 1.\n6. Unstable or life-threatening cardiac disease - participants with any of the following at Visit 1 would be excluded:\n\n   1. An MI or unstable angina in the last 8 weeks\n   2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 8 weeks.\n\n   NOTE: Any participant who experiences unstable or life-threatening cardiac disease during the run-in period will be excluded but can be rescreened 8 weeks after the resolution of the event.\n7. Pneumonia and\u002For moderate or severe COPD exacerbation that has not resolved at least 8 weeks prior to Visit 1\n8. Any life-threatening condition, including malignancy, with a life expectancy \\\u003C 5 years, other than CV disease or COPD, that might prevent the participant from completing the study.\n9. Use of maintenance ICS treatment within the past 12 months.\n10. Unable to abstain from protocol-defined prohibited medications\n11. Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer prior to Visit 1 (any other investigational product that is not identified in protocol is prohibited for use during the duration of the study).\n12. Participants with a known hypersensitivity to LAMA, LABA or ICS or any component of the MDI.\n13. Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site).\n14. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.\n15. Previous randomization in the present study.\n16. For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding","80 Years",{"count":56,"type":21},5250,"INTERVENTIONAL",[59],"PHASE3","This study will evaluate the effect of triple ICS\u002FLAMA\u002FLABA therapy with BGF MDI 320\u002F14.4\u002F9.6 μg on cardiopulmonary outcomes relative to LAMA\u002FLABA therapy with GFF MDI 14.4\u002F9.6 μg in a population with COPD and elevated cardiopulmonary risk.",[26],"RECRUITING","2026-06-23",{"date":65,"type":38},"2026-06-24",{"date":67,"type":38},"2024-02-21",{"date":69,"type":21},"2027-12-03",{"name":71,"class":45},"AstraZeneca",921,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":57,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100425460","home-based-pulmonary-rehabilitation-for-copd-patients-100425460","NCT04820257","Home-based Pulmonary Rehabilitation for COPD Patients","Inclusion Criteria:\n\n* Men and women age 40 years and older\n* FEV1 \\\u003C80% or less (forced expiratory volume in one second) as documented by pulmonary function.\n* Medical diagnosis of COPD, GOLD classification B,D, and C based on symptoms and history of exacerbations.\n* The patients must be able to access a smart-phone or computer tablet with internet service.\n\nExclusion Criteria:\n\n* Unable to perform low intensity exercise.\n* Patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency), are planning to move, are not living in the healthcare area.\n* Patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).","100 Years",{"count":81,"type":21},80,[83],"NA","Objectives The objective of this project is to motivate patients with COPD to incorporate the habit of doing daily mindful physical activity by using the proposed home-based pulmonary rehabilitation program that integrates video guided exercises, activity monitoring daily steps and health coaching. This program will allow patients to complete Pulmonary Rehabilitation (PR) at home and promote behavior change and lead to a more active lifestyle for patients with COPD who have been prescribed PR.\n\nThe program will be able to effectively monitor daily step count. A health coach will receive more this detailed data and will guide weekly health coaching sessions designed to increase awareness of the physical activities completed and ignite inner motivation for healthy behaviors.\n\nThe proposed PR program is innovative and responds to an unmet need in chronic care for COPD patients in the context of COVID-19 pandemic and it mitigates the common accessibility barriers.",[86],"COPD, Chronic Obstructive Pulmonary Disease",[88,89,90,91,92,93],"tele-health","behavioural change","motivational interviewing","home-based exercise","self-related health","quality of life",{"date":95,"type":38},"2026-06-26",{"date":97,"type":21},"2026-11-01",{"date":99,"type":21},"2028-12",{"name":101,"class":102},"Karolinska Institutet","OTHER",1,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":57,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":103},"100644308","tele-pulmonary-rehabilitation-for-copd-patients-living-in-peripheral-areas-100644308","NCT07666854","Tele-Pulmonary Rehabilitation For COPD Patients Living in Peripheral Areas","Examining the Feasibility and Effectiveness of a Remote Group Respiratory Rehabilitation Program for Patients With Chronic Obstructive Pulmonary Disease Living in Peripheral Areas as a First Step to Policy Change","TELE-PR-PRPRL","Inclusion Criteria:\n\n* Male and females Patients with COPD based on accepted criteria who are eligible for reimbursement of pulmonary rehabilitation (PR) according to the Israeli \"health basket\" criteria including one of the following:\n\n  * FEV1 below 50%\n  * Severe exacerbation (hospitalization) in the previous year\n  * Two moderate exacerbations in the previous year\n* Willingness to initiate a PR or TPR programs.\n* Living in geographic peripheral area.\n* Ability to perform the TPR program or traditional PR activities as assessed by a member of the study team prior to enrollment.\n* Agree to participate, with signed informed consent.\n* Age \\> 18.\n\nExclusion Criteria:\n\n* Uncontrolled comorbidity (e.g uncontrolled congestive heart failure).\n* Inability to operate the mobile application.\n* Without a mobile device or computer.\n* An exacerbation in the 2-months prior to randomization.\n* Completed PR program in the last 12 months.\n* Pregnancy.\n* Patients with cognitive impairment.",{"count":113,"type":21},110,[83],"Pulmonary rehabilitation (PR) is a key non-pharmacological intervention for patients with chronic obstructive pulmonary disease (COPD), yet it remains underutilized, particularly among patients living in peripheral areas due to limited access, travel distance, and logistical barriers. Tele-pulmonary rehabilitation (TPR) has the potential to improve access to care, but its feasibility and effectiveness as a group-based intervention have not been well established.\n\nThe aim of this study is to evaluate whether a group-based TPR program can improve treatment initiation and adherence compared to usual care, defined as referral to standard PR, among COPD patients living in peripheral areas. In addition, the study will assess the effect of the intervention on COPD exacerbations, symptom burden, quality of life, and patient satisfaction.\n\nThis is a prospective randomized controlled trial that will enroll patients with COPD who are eligible for PR according to the Israeli health basket criteria and have not participated in PR in the past year. Participants will be randomly assigned to one of two groups: (1) referral to standard PR (control group), or (2) participation in a 12-week, twice-weekly, group-based TPR program delivered remotely via a dedicated application and video sessions (intervention group).",[26,117,118],"Rehabilitation","Peripheral","2026-06-18",{"date":65,"type":38},{"date":122,"type":21},"2026-07-01",{"date":124,"type":21},"2028-08-01",{"name":126,"class":127},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":57,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100644283","tele-pulmonary-rehabilitation-for-patients-with-chronic-lung-diseases-100644283","NCT07666841","Tele-Pulmonary Rehabilitation For Patients With Chronic Lung Diseases","Tele-Pulmonary Rehabilitation to Improve Adherence and Management of Patients With Chronic Lung Diseases","TELE-PRIME","Inclusion Criteria:\n\n1. Patients meeting the Israeli Health Basket criteria for reimbursement of pulmonary rehabilitation (PR), including one of the following conditions:\n\n   * COPD with an FEV1 below 50% or with severe exacerbation (hospitalization) in the previous year or two moderate exacerbations in the previous year.\n   * Interstitial lung disease with an FVC below 80% or a DLCO below 60%.\n   * Bronchiectasis with at least two exacerbations in the past year or at least one hospitalization, and an FEV1 below 80%.\n   * Pulmonary arterial hypertension.\n2. Willingness to initiate a PR or Tele-PR (TPR) programs.\n3. Ability to perform the TPR program or traditional PR activities as assessed by a member of the study team prior to enrollment.\n4. Agree to participate, with signed informed consent.\n\nExclusion Criteria:\n\n1. Uncontrolled comorbidity (e.g uncontrolled congestive heart failure)\n2. Inability to operate the mobile application.\n3. Without a mobile device or computer.\n4. A hospitalization in the 2-months prior to randomization.\n5. Completed PR program in the last 12 months.\n6. Inability to complete 10 repetitions in the 1-minute sit-to-stand test or 5-second single-leg stance\n7. Pregnancy\n8. Inability to provide informed consent due to impaired decision-making capacity, as determined by the study's capacity assessment.","18 Years",{"count":138,"type":21},90,[83],"Pulmonary rehabilitation is a key treatment for lung diseases, but many patients struggle to attend sessions due to travel distances, physical limitations, or logistical barriers. The purpose of this study is to evaluate whether a tele-pulmonary rehabilitation (TPR) program can improve the rates of treatment initiation and adherence among patients with chronic lung diseases compared to traditional, center-based pulmonary rehabilitation. Additionally, the study will assess improvements in quality of life, physical symptoms, and safety in both groups.\n\nThis study will enroll 90 patients from two medical centers in Israel (Tel Aviv and Barzilai). Participants will be randomly assigned to one of two groups:\n\n1. The control group will receive usual care with a referral by a pulmonologist to standard pulmonary rehabilitation at a medical center.\n2. The intervention group will participate in a supervised remote tele-rehabilitation program using a dedicated application and remote monitoring.",[26,117,142,143,144],"Bronchiectasis Adult","Pulmonary Arterial Hypertension (PAH)","Interstitial Lung Disease (ILD)",{"date":65,"type":38},{"date":122,"type":21},{"date":148,"type":21},"2028-12-31",{"name":126,"class":127},2,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":159,"targetDuration":4,"studyType":57,"phases":161,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100641876","phase-2-a-study-of-win378-in-participants-with-moderate-to-severe-copd-sirius-100641876","NCT07646587","A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)","A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease","Sirius","Inclusion Criteria:\n\n* Adults aged 40 to 80 years\n* Post-BD spirometry at screening FEV1\u002FFVC \\\u003C 0.70 and FEV1 30-80% predicted\n* On stable triple inhaled therapy (ICS\u002FLABA\u002FLAMA) for ≥ 3 months\n* Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months\n* Elevated eosinophil count\n* Weight\u002FBMI within allowed range\n\nExclusion Criteria:\n\n* Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)\n* Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct\n* Clinically significant cardiovascular disease\n* Recent respiratory infection or COPD exacerbation\n* Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period\n* Pregnancy or breastfeeding\n* Smoking or diagnosed substance use disorder\n* Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity",{"count":160,"type":21},105,[162],"PHASE2","This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)",[26],[28,31,166,167,168,169,170],"Respiratory Disease","Monoclonal Antibody","Inflammation","TSLP","Moderate - Severe","2026-06-16",{"date":173,"type":38},"2026-06-22",{"date":175,"type":38},"2026-06-02",{"date":177,"type":21},"2028-01-07",{"name":179,"class":45},"Windward Bio",4,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":188,"targetDuration":4,"studyType":57,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":103},"100641713","phase-3-a-phase-3-clinical-trial-to-evaluate-the-safety-and-efficacy-of-hsk39004-inhalation-suspension-in-patients-with-copd-100641713","NCT07658339","A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD","A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of HSK39004 Inhalation Suspension in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)","Key Inclusion Criteria:\n\n1. Aged 40 to 80 years (inclusive) at the time of screening visit (Visit 1), male or female;\n2. Subjects diagnosed with chronic obstructive pulmonary disease (COPD) in accordance with the GOLD 2026 diagnostic criteria prior to screening \\[GOLD 2026 criteria: presence of chronic respiratory symptoms such as dyspnea, chronic cough or sputum production, and\u002For a history of risk factor exposure, and the pulmonary function test results show: the forced expiratory volume in one second (FEV1) after using bronchodilators \u002F forced vital capacity (FVC) \\\u003C0.7\\];\n3. At screening visit (Visit 1):\n\n   * Post-bronchodilator FEV1\u002FFVC \\\u003C 0.7; and\n   * Post-bronchodilator FEV1 ≥ 30% and \\\u003C 80% of predicted value;\n4. Modified Medical Research Council (mMRC) dyspnea scale score ≥ 2 at screening;\n\nKey Exclusion Criteria:\n\n1. Known hypersensitivity to HSK39004 inhalation suspension, salbutamol, or any component of the drug delivery system;\n2. History of life-threatening acute exacerbation of COPD;\n3. Acute exacerbation of COPD (excluding the use of short-acting bronchodilators alone) or hospitalization for pneumonia within 12 weeks prior to screening (Visit 1);\n4. Acute (viral or bacterial) upper or lower respiratory tract infection within 6 weeks prior to screening (Visit 1);\n5. Diagnosis of any other clinically significant respiratory disease besides COPD, including but not limited to: alpha-1 antitrypsin deficiency, bronchial asthma, active tuberculosis, lung cancer, pulmonary edema, cystic fibrosis, bronchiolitis obliterans, pulmonary sarcoidosis, or clinically significant idiopathic pulmonary fibrosis, pulmonary arterial hypertension, bronchiectasis (except asymptomatic localized bronchiectasis) that, in the opinion of the investigator, poses a safety risk to the participant or may affect the analysis of study result;\n6. Severe or uncontrolled cardiovascular disease or history;\n7. History of malignancy (except for carcinoma in situ, cutaneous squamous cell carcinoma, and basal cell carcinoma cured for more than 5 years), suspected malignancy, or undetermined neoplasm;\n8. Concurrent severe, uncontrolled renal, neurological, endocrine, thyroid, urological, ophthalmic, immunological, psychiatric, gastrointestinal, hepatic, or hematological diseases\u002Fabnormalities that, in the investigator's judgment, may pose a safety risk to the subject or confound study outcome analysis;\n9. History of lung lobectomy or lung volume reduction surgery within 12 months prior to screening;\n10. Subjects determined by the investigator to require oxygen therapy;\n11. Clinically significant sleep apnea requiring continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV)",{"count":189,"type":21},387,[59],"The purpose of this study is to evaluate the efficacy and safety of HSK39004 Inhalation Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).",[26],[194],"PDE3\u002F4","2026-06-15",{"date":173,"type":38},{"date":198,"type":21},"2026-07-11",{"date":200,"type":21},"2027-06-11",{"name":202,"class":45},"Haisco Pharmaceutical Group Co., Ltd.",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100576035","study-that-will-evaluate-the-brazilian-population-with-copd-100576035","NCT06780046","Study That Will Evaluate the Brazilian Population With COPD.","Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil.","SCOPe","Inclusion Criteria:\n\n* Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1\u002FFVC =2 or CAT \\>=10); or\n* GOLD E (\\>=2 moderate or 1 severe exacerbation - hospitalization); or\n* GOLD 3 and 4 (FEV1 \\\u003C50%).\n\nExclusion Criteria:\n\n* Advanced fibrosing interstitial lung disease (extent \\>=50%); and\u002For\n* High-risk pulmonary hypertension (on triple therapy); and\u002For\n* Active cancer - on systemic therapy",{"count":212,"type":21},693,"Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.",[26],"2026-06-11",{"date":217,"type":38},"2026-06-12",{"date":219,"type":38},"2025-01-31",{"date":221,"type":21},"2027-09-30",{"name":71,"class":45},10,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":231,"targetDuration":4,"studyType":57,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":103},"100643469","phase-3-a-multicenter-randomized-double-blind-placebo-controlled-parallel-group-phase-iii-study-of-hsk39004-inhalation-powder-for-the-treatment-of-copd-100643469","NCT07583849","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD","A Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK39004 Inhalation Powder in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Design","Inclusion Criteria:\n\n* 1)During the screening visit (Visit 1), the age range is 40 to 80 years (including the threshold value), and gender is not restricted; 2) The body mass index is within the range of 18 to 30 kg\u002Fm2 (including the threshold value); 3) The subjects with chronic obstructive pulmonary disease (COPD) as per the GOLD 2025 diagnostic criteria, and the symptoms before screening were consistent with COPD for at least 1 year \\[GOLD 2025 standard: the subjects have chronic respiratory symptoms such as shortness of breath, chronic cough or expectoration, and\u002For have a history of exposure to risk factors, and the pulmonary function test results show: the forced expiratory volume in one second (FEV1) after using bronchodilators \u002F forced vital capacity (FVC) \\\u003C0.7\\]; 4) During the screening visit (Visit 1):\n\n  * FEV1\u002FFVC after using bronchodilators is \\\u003C0.7;\n  * 30% of the expected value ≤ FEV1 after using bronchodilators \\\u003C 80% of the expected value; Note: Using bronchodilators refers to using 400 μg (4 puffs, 100 μg per puff, with an interval of 1 minute between each puff) salbutamol inhalation aerosol for 15 to 30 minutes after use.\n\n    5\\) At the time of screening, the modified British Medical Research Council (mMRC) dyspnea scale score is ≥ 2; 6）Current smokers with a smoking quantity of ≥ 10 packs per year (smoking index (pack years) = daily smoking quantity (packs) × time (years), 1 pack = 20 cigarettes), or former smokers (for example: at least 1 pack per day, for 10 years), or those with a history of exposure to other risk factors.\n\nExclusion Criteria:\n\n* 1） Lactose\u002Fmilk protein (dairy products) intolerance, allergy to HSK39004 inhalation powder or salbutamol or any known components in the administration system; 2）Have received treatment for COPD acute exacerbation or been hospitalized for pneumonia within 12 weeks before screening; 3) Have had acute (viral or bacterial) upper or lower respiratory tract infections or other infectious diseases requiring antibiotic treatment within 6 weeks before screening; 4) Have other diagnosed respiratory system diseases other than COPD, including but not limited to: α-1 antitrypsin deficiency, asthma, active tuberculosis, lung edema, cystic fibrosis, bronchiectasis, pulmonary nodular disease, or clinically significant pulmonary fibrosis, pulmonary hypertension, interstitial lung disease, bronchiectasis (excluding asymptomatic local bronchial dilation); 5) Have a history of or currently have severe cardiovascular diseases, including but not limited to:\n\n  * Screening period NYHA cardiac function grade III\u002FIV (according to the NYHA cardiac function grading standard, see Appendix 1);\n  * Had acute myocardial infarction, unstable angina pectoris\u002Facute coronary syndrome, percutaneous coronary intervention, coronary artery bypass grafting within 6 months before screening;\n  * Structural heart disease, such as hypertrophic cardiomyopathy, moderate to severe valvular disease;\n  * Had severe arrhythmia within 3 months before screening, such as: atrial fibrillation with a ventricular rate \\> 120 bpm, ventricular tachycardia, bradycardia (ventricular rate \\\u003C 45 bpm), second-degree II or above atrioventricular conduction block (excluding those with implanted pacemaker or defibrillator), male QTcF \\> 450 ms or female QTcF \\> 470 ms;\n  * Subjects with poor blood pressure control (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg at the screening visit); 6) Have type I diabetes or poorly controlled type II diabetes (fasting blood glucose ≥ 10 mmol\u002FL at screening); 7) Have cancer (in situ cancer that has been cured for more than 5 years, skin squamous cell carcinoma and basal cell carcinoma, etc., except for subjects with suspected malignant tumors or undetermined tumors); 8) Combine other severe unstable kidney, nervous system, endocrine diseases, thyroid diseases, urinary system, ophthalmic diseases, immune system, mental system, gastrointestinal, liver or blood system disease\u002Fabnormal history, as determined by the investigator, participation in this study may pose risks to the subjects or affect the analysis of research results; 9) During the screening period (visit 1), the investigator determines that the laboratory tests of the subjects show clinically significant abnormalities that may pose risks to the subjects, including but not limited to the following situations:\n\n    1. The glomerular filtration rate (eGFR) calculated using the CKD-EPI formula is less than 60 mL\u002Fmin\u002F1.73m2;\n    2. Liver function: Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) are more than 2.5 times the upper limit of the normal value; Total bilirubin (TBIL) is more than 1.5 times the upper limit of the normal value.\n\n       10\\) Within 12 months before screening, received lobectomy or lung volume reduction surgery; 11) Had major surgery (requiring general anesthesia) within 6 weeks before screening, not fully recovered at the time of screening, or planned to undergo surgery before the end of the study; 12) Patients determined by the investigator to require oxygen therapy; 13）Have clinically significant apnea that requires the use of a continuous airway positive pressure ventilation (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device;",{"count":232,"type":21},376,[59],"To evaluate the efficacy and safety of a 12-week administration of HSK39004 inhalation powder in clinical trial participants with COPD",[26],"2026-06-08",{"date":238,"type":38},"2026-06-10",{"date":240,"type":38},"2026-05-24",{"date":242,"type":21},"2027-10-30",{"name":202,"class":45},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":251,"targetDuration":4,"studyType":57,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":103},"100643596","phase-3-long-term-safety-and-efficacy-of-hsk39004-inhalation-suspension-in-copd-100643596","NCT07634367","Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD","A Multicenter, Single-Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Key Inclusion Criteria:\n\n1. 40 to 80 years (inclusive) at the time of screening visit (Visit 1), male or female;\n2. Subjects diagnosed with chronic obstructive pulmonary disease (COPD) in accordance with the GOLD 2026 diagnostic criteria prior to screening \\[GOLD 2026 criteria: presence of chronic respiratory symptoms such as dyspnea, chronic cough or sputum production, and\u002F or a history of risk factor exposure, and the pulmonary function test results show: the forced expiratory volume in one second (FEV1) after using bronchodilators \u002F forced vital capacity (FVC) \\\u003C0.7\\];\n3. At screening visit (Visit 1):\n\n   Post-bronchodilator FEV1\u002FFVC \\\u003C 0.7; and Post-bronchodilator FEV1 ≥ 30% and \\\u003C 80% of predicted value;\n4. Modified Medical Research Council (mMRC) dyspnea scale score ≥ 2 at screening;\n\nKey Exclusion Criteria:\n\n1. Subjects with unresolved lower respiratory tract infection occurring within 6 weeks prior to screening (Visit 1) and\u002For before enrollment;\n2. Severe or uncontrolled cardiovascular disease or history, including but not limited to: New York Heart Association (NYHA) functional class III\u002FIV at screening; acute myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to screening; clinically significant arrhythmia requiring intervention or marked QTcF prolongation (male \\>450 ms, female \\>470 ms) within 3 months prior to screening; or unstable or uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg) at screening;\n3. History of malignancy (except for carcinoma in situ, cutaneous squamous cell carcinoma, and basal cell carcinoma cured for more than 5 years), suspected malignancy, or undetermined neoplasm;\n4. Concurrent severe, uncontrolled renal, neurological, endocrine, thyroid, urological, ophthalmic, immunological, psychiatric, gastrointestinal, hepatic, or hematological diseases\u002Fabnormalities that, in the investigator's judgment, may pose a safety risk to the subject or confound study outcome analysis;\n5. Known hypersensitivity to HSK39004 inhalation suspention, salbutamol, or any component of the drug delivery system;\n6. Use of any protocol-prohibited medication prior to spirometry at screening (Visit 1);\n7. History of lung lobectomy or lung volume reduction surgery within 12 months prior to screening;\n8. Major surgery (requiring general anesthesia) within 6 weeks prior to screening with incomplete recovery, or planned surgery before study completion;\n9. Subjects determined by the investigator to require oxygen therapy;\n10. Clinically significant sleep apnea requiring continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV)",{"count":252,"type":21},300,[59],"This clinical trial evaluates the long-term safety and efficacy of 3 mg HSK39004 Inhalation Suspension administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive pulmonary disease (COPD).",[26],[194],"2026-06-03",{"date":236,"type":38},{"date":260,"type":21},"2026-07-10",{"date":262,"type":21},"2027-12-24",{"name":202,"class":45},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":180},"100602038","copd-exacerbation-follow-up-100602038","NCT07118306","COPD Exacerbation Follow Up","A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization","Inclusion Criteria:\n\n* Patients aged 40 years or older at the time of arrival to the emergency department.\n* Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.\n* A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and\u002For antibiotics.\n* A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \\>24 hours in emergency department\u002Furgent care facility or resulting in death.\n* Patients on dual (LABA\u002FLAMA, LABA\u002FICS, LAMA\u002FICS) or triple (LABA\u002FLAMA\u002FICS) long-acting bronchodilator inhalers.\n\nExclusion Criteria:\n\n* Patients on bronchodilator inhaler monotherapy.\n* Patients leaving against medical advice or expiring during hospitalization.\n* Patients with tracheostomy.\n* Patients with advanced cancer.\n* Patients who have received a lung transplant.\n* Discharge to hospice care.\n* Transfer to another hospital.",{"count":272,"type":21},485,"The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.",[26],[28,276,32,277],"Chronic obstructive pulmonary disease","VizCOPD",{"date":257,"type":38},{"date":280,"type":38},"2026-02-27",{"date":282,"type":21},"2027-12",{"name":284,"class":45},"Viz.ai, Inc.",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":57,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":103},"100638425","effectiveness-of-combined-concentric-and-eccentric-aerobic-exercise-on-a-treadmill-in-patients-with-copd-a-randomized-clinical-trial-100638425","NCT07627035","EFFECTIVENESS OF COMBINED CONCENTRIC AND ECCENTRIC AEROBIC EXERCISE ON A TREADMILL IN PATIENTS WITH COPD: A RANDOMIZED CLINICAL TRIAL.","Inclusion Criteria: • Subjects \\>18 years old.\n\n* Present with dyspnea grade 2-3 on the mMRC scale.\n* Sufficient cognitive and functional level to understand, learn, and carry out the exercise program.\n* No contraindications to physical training.\n* Active participants.\n\nExclusion Criteria: • Recent cardiovascular events such as congestive heart failure, angioplasty or cardiac surgery within the last four weeks, valvular abnormalities requiring surgical correction, myopericarditis, or exercise-induced ventricular arrhythmias.\n\n* Renal failure requiring dialysis.\n* Patients with uncontrolled bronchospasm due to intrinsic asthma.\n* Patients undergoing chemotherapy after surgery.\n* Severe exercise intolerance due to untreated cardiac arrhythmias, ischemia during low-intensity exercise (unstable angina), severe pulmonary hypertension, or heart failure (NYHA class III or IV).\n* Pulmonary embolism with anticoagulant therapy for less than 5 days.",{"count":292,"type":21},40,[83],"The aim of this study is to demonstrate the effectiveness of combined concentric and eccentric aerobic training in subjects with COPD, in terms of strength, lung capacity, functionality, and short-term health quality. A randomized, examiner-blinded clinical trial has been designed for this purpose, following the CONSORT guidelines for clinical trials and the ethical principles of the Declaration of Helsinki. A total sample of 40 subjects has been estimated. The study is aimed at patients diagnosed with mild or moderate COPD. A program of 12 group sessions will be conducted over 4 weeks. Each session will last 75 minutes and will include strength exercises and respiratory physiotherapy, common to all subjects. The interval aerobic training will depend on the assigned group: treadmill with negative and positive (or neutral) incline (experimental group), treadmill with positive incline and\u002For cycle ergometer (control group). The following variables will be measured on the first and last day of treatment, as well as one month after the intervention ends: thickness, cross-sectional area, and ultrasound intensity of the rectus femoris muscle; diaphragmatic excursion and thickness; 5 sit to stand test; get up and go test; Borg scale; maximum respiratory pressures; grip strength in both hands and maximum quadriceps strength; spirometric assessment of FEV1 and SF-12 health quality questionnaire.",[26,296,297],"Pulmonary Rehabilitation","Eccentric Exercise Training","2026-05-31",{"date":300,"type":38},"2026-06-04",{"date":302,"type":21},"2026-09",{"date":304,"type":21},"2028-09",{"name":306,"class":102},"Universidad Europea de Madrid",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":315,"maxAge":54,"enrollmentInfo":316,"targetDuration":4,"studyType":57,"phases":318,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":150},"100637685","isoinertial-training-in-patients-with-copd-100637685","NCT07605117","Isoinertial Training in Patients With COPD","Effect of Isoinertial Training on Muscle Strength and Functional Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Randomized Controlled Clinical Trial","ISTrainingCOPD","Inclusion Criteria:\n\n* People between 50 - 80 years of age diagnosed with moderate or severe COPD\n* No acute exacerbations in the last 4 weeks\n* Sufficient functional capacity to exercise\n* Signed informed consent\n\nExclusion Criteria:\n\n* Presence of neurological, musculoskeletal, or cardiovascular diseases that significantly limit exercise performance or compromise participant safety; including uncontrolled hypertension, recent myocardial infarction, unstable angina, severe osteoarthritis, stroke sequelae, or Parkinson's disease.\n* Contraindications to exercise participation according to medical evaluation.\n* Recent surgeries in the past 3 months\n* Simultaneous participation in other exercise programs\n* Cognitive disorders","50 Years",{"count":317,"type":21},30,[83],"Isoinertial training is emerging as a potentially effective strategy to improve strength and functionality in older people diagnosed with chronic obstructive pulmonary disease (COPD), due to its influence on muscle mass and neuromuscular efficiency. COPD is characterized by systemic alterations, including peripheral muscle dysfunction; which contributes to patient functional limitation, and reduces patients' quality of life. Isoinertial training may improve the physiological response to effort, and also promote functional performance in this population. Hence, the aim of this study is to evaluate the effect of an isoinertial training program on muscle strength and functional capacity in patients with COPD during an 8-week intervention.",[26],[322,323,296,324,325,326,327,328],"Muscle Strength","Functional Capacity","Interventional study","Adults","Exercise","Flywheel training","Lung Disease","2026-05-26",{"date":331,"type":38},"2026-05-29",{"date":333,"type":21},"2026-05-07",{"date":335,"type":21},"2026-07-27",{"name":337,"class":102},"Universidad Manuela Beltrán",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":346,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":103},"100640617","quantitative-chest-ct-and-multi-omics-to-distinguish-asthma-from-copd-and-predict-treatment-response-100640617","NCT07602192","Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response","Prospective Multicenter Cohort to Discriminate Asthma Versus Chronic Obstructive Pulmonary Disease and Predict Treatment Response Using Quantitative Chest CT and Multi-Omics","CTOMICS","Inclusion Criteria:\n\n* Age ≥19 years\n* COPD group: post-bronchodilator FEV1\u002FFVC \\\u003C 0.70\n* Asthma group: clinically confirmed diagnosis of asthma by a physician\n* Able to provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks\n* Pregnancy or breastfeeding\n* Inability to undergo chest CT (e.g., poor cooperation or severe medical condition)\n* Refusal to consent to study procedures","19 Years",{"count":348,"type":21},200,"This study aims to improve the diagnosis and treatment prediction of asthma and chronic obstructive pulmonary disease (COPD) by combining quantitative chest computed tomography (CT) imaging with multi-omics data.\n\nAdults with asthma or COPD will be enrolled and undergo routine clinical evaluations, pulmonary function tests, blood tests, and chest CT scans. Additional samples, such as sputum and microbiome specimens, may also be collected. No experimental drugs or devices will be administered as part of this study.\n\nResearchers will analyze CT imaging features together with clinical, laboratory, and biological data to better distinguish asthma from COPD and to identify factors that may predict treatment response. The findings are expected to contribute to more precise and personalized management of chronic airway diseases.",[351,26],"Asthma (Diagnosis)",[353,354,355,31,356],"Quantitative chest CT","Airway disease","Asthma","Treatment response","2026-05-20",{"date":359,"type":38},"2026-05-22",{"date":361,"type":38},"2025-12-22",{"date":363,"type":21},"2027-12-22",{"name":365,"class":102},"Korea University Guro Hospital",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":57,"phases":376,"briefSummary":377,"conditions":378,"keywords":381,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":103},"100637232","phase-3-analysis-of-growth-differentiation-factor-15-gdf-15-mid-regional-proadrenomedullin-mr-proadm-and-persepsin-levels-in-patient-in-acute-coronary-syndrome-patients-with-pneumonia-with-or-without-influenza-vaccination-100637232","NCT07604103","Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination","Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination","Inclusion Criteria:\n\n* Adult male patients (\\\u003C 65 years old).\n* History of being an active smoker.\n* Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.\n* Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.\n* Willing to undergo all study procedures and sign the Informed Consent form.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components).\n* Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy.\n* Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values.\n* Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase.\n* Patient death before the observation period (up to post-vaccination) is completed.\n* Patient unilaterally resigns or withdraws consent during the study.\n* Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.","65 Years",{"count":375,"type":21},60,[59],"The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations.\n\nThe main questions it aims to answer are:\n\n* Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients?\n* How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations.\n\nParticipants will:\n\n\\- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.",[379,380,26],"Acute Coronary Syndromes (ACS)","Pneumonia",[382,383,384,385,380,386],"GDF-15","MR proADM","Persepsin","Acute coronary syndrome","influenza vaccination","2026-05-16",{"date":359,"type":38},{"date":390,"type":38},"2026-01-01",{"date":392,"type":21},"2026-10-10",{"name":394,"class":102},"University of Brawijaya",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":57,"phases":404,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100638719","pulmonary-rehabilitation-frequency-in-copd-patients-100638719","NCT07575841","Pulmonary Rehabilitation Frequency in COPD Patients","Comparative Efficacy of a Supervised Pulmonary Rehabilitation Program Performed 3 Days\u002FWeek Versus 1 Day\u002FWeek in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized Clinical Trial","IInclusion criteria\n\n* Diagnosis of COPD confirmed by spirometry (FEV₁\u002FFVC \\\u003C0.70)\n* Modified Medical Research Council (mMRC) dyspnoea scale ≥2\n* Ability to actively participate and perform physical exercise\n* Signed informed consent\n\nExclusion criteria\n\n* Unstable cardiac or musculoskeletal comorbidity contraindicating or limiting exercise\n* Moderate to severe cognitive impairment or inability to understand instructions\n* Recent participation (\\\u003C6 months) in a complete pulmonary rehabilitation programme\n* Inability to attend the centre 1-3 days\u002Fweek according to group allocation\n* Current participation in any structured pulmonary rehabilitation programme or supervised rehabilitation intervention in another centre.\n* Active oncological treatment",{"count":403,"type":21},158,[83],"Chronic obstructive pulmonary disease (COPD) is a common condition that can cause breathlessness and reduced physical capacity. Pulmonary rehabilitation (PR) is an effective treatment, but traditional programs often require patients to attend sessions several times per week, which may limit participation.\n\nThis study aims to compare the effectiveness of two supervised pulmonary rehabilitation programs: one performed 3 days per week and another performed 1 day per week, both over an 8-week period and including additional home-based exercises.\n\nThe main objective is to determine whether the lower-frequency program is not inferior to the higher-frequency program in improving functional capacity, measured by the six-minute walk test. Secondary outcomes include dyspnea, quality of life, muscle strength, physical activity, adherence, exacerbations, and safety.\n\nThe results of this study may help optimize pulmonary rehabilitation programs and improve accessibility for patients with COPD.",[28,26],[28,408,409,410,296],"Exercise training","Supervised Exercise","Home-based Rehabilitation","2026-05-04",{"date":413,"type":38},"2026-05-08",{"date":415,"type":21},"2027-01",{"date":417,"type":21},"2028-08",{"name":419,"class":102},"Hospital Universitario Fundación Alcorcón",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":57,"phases":430,"briefSummary":431,"conditions":432,"keywords":437,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":180},"100576240","phase-2-psilocybin-therapy-for-psychological-distress-in-palliative-patients-100576240","NCT06782724","Psilocybin Therapy for Psychological Distress in Palliative Patients","The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.","PsyPal","Inclusion Criteria:\n\n1. Patient has to be diagnosed with one of the following four conditions, defined as:\n\n   COPD i) Diagnosis by medical specialist ii) Postbronchodilator FEV1\u002FFVC \\\u003C 0,7 and FEV1 \\\u003C80% pred iii) ≥ 40 years old iv) ≥ 10 years smoking\n\n   ALS i) ALS according to Goldcoast criteria (Shefner et al, Clin Neurophysiol, 2020) ii) ALS-FRS-R subscores of minimum 1 in item 2, 3 and 8, subscore of minimum 2 in item 1, 4 and 10 and a subscore of minimum 3 in item 11 and 12\n\n   MS i) Fulfilled diagnostic revised McDonald criteria for MS from 2017 (Thompson et al., 2018) ii) EDSS ≥ 1,0\n\n   APD i) Advanced to Late-Stage Parkinson's Disease - patients with a diagnosis of Parkinson's Disease per the MDS clinical diagnosis criteria with evidence of motor and non-motor fluctuations ii) Diseases in the spectrum of Progressive supranuclear palsy (PSP), fulfilling possible and probable criteria, according to the MDS diagnostic criteria iii) Clinically Established and Clinically Probable Multiple System Atrophy (MSA) according to the MDS diagnostic criteria\n2. Patient meets ICD-10 criteria for major depressive disorder documented through the com-pletion of the mood section of the Mini International Neuropsychiatric Interview by a screen-ing psychologist or physician.\n3. Patient has a MADRS score of \\> 19.\n4. Patient should have a life expectancy of at least 6 months (assessed by study physician).\n5. Patient is at least 18 years of age.\n6. Patient has an identified caregiver\u002Fsupport person. See specific conditions for Czechia in Appendix 5.\n7. Patient is able to read and understand the informed consent and all scales used in a local language. For those with ALS, MS, or APD, competency is ensured via neurologist assessment, cognitive screening, caregiver support during screening and interactive approaches where the screening clinician ask the patient to explain their understanding of consent elements, re-explaining potentially misunderstood information.\n8. Patient is able to and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.\n9. Patient is able to ingest capsules.\n\nExclusion Criteria:\n\n1. Patient has used a psychedelic substance in the past 6 months (e.g., psilocybin, LSD, 5-MeO-DMT, DMT, ayahuasca or mescaline).\n2. Patient is in active treatments for other psychiatric disorders, judged by the screening clinician to be a more significant clinical problem than depression \u002F distress.\n3. Patient meets ICD-10 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features (except substance\u002Fmedication-induced or due to another medical condition) or bipolar I\u002FII disorder.\n4. Patients with any lifetime diagnosis of schizophrenia spectrum or other psychotic disorders.\n5. Patient has a first-degree relative with schizophrenia spectrum, bipolar I disorder or other psychotic disorders (expect substance\u002Fmedication-induced or due to another medical condition).\n6. Patients with a pre-existing psychiatric condition judged to be incompatible with safe exposure to psilocybin therapy.\n7. Significant suicide risk as defined by (1) suicidal ideation with intent to act (defined as ≥ 5 on MADRS item 10), (2) suicidal attempts within the past year, or (3) clinical assessment of significant suicidal risk during patient interview.\n8. Patient meets ICD-10 criteria for active\u002Fcurrent alcohol or drug use disorder.\n9. Patient has ongoing treatment with antipsychotic drugs. Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug at the time of baseline (see Appendix 1a for Prohibited medications).\n10. Patient is unwilling or unable to pause formal psychotherapy (days 0-42).\n11. Patient has neurological conditions (e.g., intracranial tumour, epilepsy, brain injuries, or other neurological disorders) expected by the PIs to conflict with the treatment \u002F study protocol.\n12. Disease-specific exclusion criteria:\n\n    COPD: Unresolved exacerbation or pulmonary infection within last 4 weeks. ALS: Significant cognitive deficits (MoCa, see below). MS: Significant cognitive deficits (MoCa, see below), epilepsy or radiologically isolated syndrome.\n\n    APD: Dementia (MoCa, see below), or Schwab and England ADL scale with scores \\> 80% in the best functional state.\n13. Cardiovascular conditions: recent stroke (\\\u003C 1 year from signing of ICF), recent myocardial infarction (\\\u003C 1 year from signing of ICF), uncontrolled hypertension (blood pressure \\> 140\u002F90 mmHg), clinically significant arrhythmia within 1 year of signing the ICF, or QTc prolongation exceeding 450ms (males) \u002F 470ms (females).\n14. Patient has moderate to severe hepatic impairment (Child-Pugh score ≥ 7).\n15. Patient has insulin-dependent diabetes or who are taking oral hypoglycaemic agents and have a current risk of hypoglycaemia that would require medical intervention.\n16. Patient has any physical or psychological symptoms, medications, blood test results or clinically significant findings at Screening or Baseline (based on the clinical judgement of clinical\u002Fmedical study personnel) that would make a patient unsuitable for the study.\n17. Patient has an allergy or intolerance to any of the materials contained in either drug product.\n18. Cognitive and Neuropsychological assessment: Patients will be excluded if they score below mean minus 1.5 Standard Deviation according to normative age and scholarity adjusted data on the Montreal Cognitive Assessment (MoCA) assessment.\n19. Recent (2 weeks) change or planned change in antidepressant medication during the intervention.\n20. Women who are pregnant, intend to become pregnant during the study or who are currently nursing, or are unwilling to use Highly Effective Contraceptive Methods",{"count":429,"type":21},108,[162],"The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy. The main questions it aims to answer are:\n\n* Can psilocybin therapy safely reduce depressive symptoms compared to low-dose control?\n* Will the therapeutic effects be rapid and sustained over a 6-month period?\n\nResearchers will compare patients receiving two escalating doses of psilocybin (15mg followed by 25mg) against those receiving two low doses (1mg) to see if the higher doses lead to greater improvements in depression, anxiety, demoralization, and quality of life.\n\nParticipants will:\n\n* Attend three preparation sessions with psychotherapists (1-2 hours each)\n* Undergo two supervised psilocybin dosing sessions (6-8 hours each)\n* Complete five integration therapy sessions following the dosing sessions\n* Participate in follow-up assessments at 6 weeks, 3 months, and 6 months\n* Have access to a digital care platform and peer support groups during the 6-month follow-up period\n* Optional: Control group participants may receive one high-dose psilocybin session (25mg) after the initial study period",[26,433,434,435,436],"ALS (Amyotrophic Lateral Sclerosis)","MS (Multiple Sclerosis)","Major Depressive Disorder (MDD)","Atypical Parkinson Disease",[438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456],"psilocybin","therapy","palliative","care","palliative care","end-of-life distress","depression","psychological distress","psypal","copd","als","ms","apd","chronic obstructive pulmonary disorder","amyotrophic lateral sclerosis","multiple sclerosis","major depressive disorder","atypical parkinson disease","existential distress",{"date":413,"type":38},{"date":459,"type":38},"2025-07-01",{"date":461,"type":21},"2028-01-01",{"name":463,"class":102},"University Medical Center Groningen",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":471,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":472,"targetDuration":473,"studyType":23,"phases":4,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":103},"100636645","multidimensional-study-of-dyspnea-at-rest-during-exertion-self-induced-through-a-virtual-reality-scenario-and-its-placebo-effect-in-patients-with-copd-and-control-subjects-100636645","NCT07568379","Multidimensional Study of Dyspnea at Rest, During Exertion, Self-induced Through a Virtual Reality Scenario, and Its Placebo Effect in Patients With COPD and Control Subjects.","DisVir","Inclusion Criteria:\n\nCOPD:\n\n* Diagnosed COPD (FEV1\u002FFVC \\\u003C 0.7 post-bronchodilator)\n* GOLD stage 2-4\n* Clinically stable\n* Signed informed consent\n\nHealthy subjects:\n\n* Normal pulmonary function\n* No chronic diseases\n* Non-smoker or long-term ex-smoker\n\nExclusion Criteria:\n\nCOPD patients:\n\n* Severe cardiac, neurological, or psychiatric disease\n* Other respiratory diseases\n* Recent exacerbation\n* Use of ventilatory support (except CPAP)\n\nHeatlhy subjects:\n\n* Respiratory symptoms\n* Recent infections\n* Medication affecting respiratory function\n* Substance abuse",true,{"count":81,"type":21},"5 Days","This quasi-experimental laboratory study aims to describe and compare the multidimensional experience of dyspnea at rest and during exertion in patients with chronic obstructive pulmonary disease (COPD) and healthy controls. The study integrates neurophysiological, somatosensory, and psychological assessments, including prefrontal cortex activity (fNIRS), quantitative sensory testing (QST), and immersive virtual reality (VR) scenarios.\n\nAdditionally, the study evaluates the modulation of dyspnea perception through expectation mechanisms and placebo intervention using high-flow nasal cannula (HFNC). The ultimate goal is to better understand the multidimensional and neurocognitive mechanisms underlying dyspnea.",[26],[28,477,478,479,480,481],"Dyspnea","Virtual reality","fNRIS","QST","Respiratory function","2026-04-30",{"date":484,"type":38},"2026-05-05",{"date":486,"type":21},"2026-04",{"date":488,"type":21},"2028-01",{"name":490,"class":102},"University of Deusto",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":499,"targetDuration":4,"studyType":57,"phases":500,"briefSummary":501,"conditions":502,"keywords":508,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":4},"100620748","the-revive-pivotal-study-100620748","NCT07361653","The REVIVE Pivotal Study","A Prospective, Global, Multicenter, Randomized, Double Blind, Sham Controlled Study to EValuate the Safety and effectIVEness of the Ryme Medical Targeted Lung Denervation (TLD) Catheter in Patients With Moderate and Severe Symptomatic Chronic Obstructive Pulmonary Disease (COPD) - The REVIVE Pivotal Study","REVIVE","Inclusion Criteria:\n\n* Symptomatic chronic obstructive pulmonary disease\n* History of COPD exacerbation(s)\n* Stable medical therapy\n* Candidate for bronchoscopy\n\nExclusion Criteria:\n\n* Prior lung intervention with device in place\n* Using tobacco products, e-cigarettes, vape or other inhaled non-pharmacological substance\n* Clinically significant serious or unstable medical conditions (e.g., heart disease requiring treatment, uncontrolled diabetes)\n* Pregnant, nursing, or intent to become pregnant during study duration",{"count":252,"type":21},[83],"The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).\n\nThe main questions it aims to answer are:\n\n1. Does the TLD Catheter improve symptoms in people with COPD?\n2. Is the TLD Catheter safe ?\n\nResearchers will compare the group receiving the TLD treatment to the group receiving a sham procedure to see if the treatment improves quality of life.\n\nParticipants will:\n\n1. Be randomly assigned to receive either the TLD treatment or a sham procedure.\n2. Undergo the assigned procedure in a hospital setting.\n3. Attend follow-up visits for health checks and breathing tests.",[26,503,504,505,28,506,507],"COPD Exacerbations","COPD Patients","COPD Acute Exacerbation","Lung Disease Airways","Lung Disease, Chronic Obstructive",[28,509,31],"Targeted Lung Denervation","2026-04-29",{"date":484,"type":38},{"date":513,"type":21},"2026-06",{"date":515,"type":21},"2029-12",{"name":517,"class":45},"Ryme Medical, Inc.",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":103},"100612461","a-study-to-understand-the-accuracy-of-a-new-breathing-device-compared-to-standard-testing-for-asthma-and-copd-100612461","NCT07253883","A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD","A Diagnostic Accuracy Study: N-Tidal Assessment for Respiratory Diagnosis Compared to Using Standard Testing","STARDUST","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Referred for respiratory diagnostic testing with a clinical suspicion of asthma or COPD\n* Participant is willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Referred for respiratory diagnostic testing for a condition other than asthma or COPD, with no mention in the referral of a clinical suspicion of COPD or asthma\n* Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study\n* Inability to give written informed consent\n* Participants who are acutely unwell\n* Patients unable to breathe through their mouths e.g. tracheostomy patients","110 Years",{"count":528,"type":21},1200,"The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one.\n\nThe STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study.\n\nAfter the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms.\n\nIf confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.",[351,26],[355,28,532,533,534],"End tidal CO2","Diagnostics","Machine learning","2026-04-21",{"date":537,"type":38},"2026-04-24",{"date":539,"type":21},"2026-04-01",{"date":541,"type":21},"2027-05-19",{"name":543,"class":102},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":57,"phases":554,"briefSummary":555,"conditions":556,"keywords":567,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":103},"100634739","enhanced-copd-management-in-suspected-lung-cancer-patients-100634739","NCT07543601","Enhanced COPD Management in Suspected Lung Cancer Patients","Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention","ECHELON","Inclusion Criteria:\n\n* Undergoing diagnostic evaluation for suspected lung cancer\n* Spirometry showing obstructive airflow limitation (FEV₁\u002FFVC \\\u003C 75 % or FEV₁ \\\u003C 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation\n\nExclusion Criteria:\n\n* Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry\n* Pregnant or breastfeeding women",{"count":553,"type":21},280,[83],"Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.\n\nThis study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.\n\nThe findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.",[26,557,558,559,560,561,562,563,564,28,565,566],"Lung Cancer (Diagnosis)","Lung Neoplasm Malignant","Lung Carcinoma","Pulmonary Neoplasms","Pulmonary Neoplasm","Pulmonary Cancers","Pulmonary Cancer","Pulmonary Carcinoma","COPD - Chronic Obstructive Pulmonary Disease","Airflow Obstruction, Chronic",[568,569,570,571],"Invesigation","Evaluation","Diagnostic Work-up","Diagnostic Pathway","2026-04-15",{"date":574,"type":38},"2026-04-22",{"date":576,"type":38},"2026-03-06",{"date":578,"type":21},"2027-06-30",{"name":580,"class":102},"Ditte Krag-Hansen",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":603,"locationsCount":103},"100624162","real-world-effectiveness-of-a-triple-combination-bdpffgb-extrafine-in-a-single-pressurised-metered-dose-inhaler-in-brazilian-copd-patients-100624162","NCT07406048","Real-World Effectiveness of a Triple Combination BDP\u002FFF\u002FGB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","A Real-World Study Evaluates the Clinical Characteristics and Effectiveness of COPD Patients Treated With the Triple Combination Beclometasone Diproprionate\u002FFormoterol Fumarate\u002FGlycopyrronium Bromide (BDP\u002FFF\u002FGB) in a Single Pressurised Metered Dose Inhaler (Trimbow® pMDI) in Brazil","RETRIBUTE","Inclusion Criteria:\n\n* Male and Female patients ≥ 40 years old at the time of BDP\u002FFF\u002FGB initiation\n* Patients with documented diagnosis of severe or very severe COPD prior to BDP\u002FFF\u002FGB initiation\n* Patients with CAT total score ≥ 10 at baseline (at the time of BDP\u002FFF\u002FGB initiation or within the 12 months before treatment initiation\\*) \\*If no CAT total score is available on BDP\u002FFF\u002FGB initiation date)\n* Patients with at least ≥ 1 COPD exacerbation within the previous 12 months before enrollment.\n* Patients who started treatment with BDP\u002FFF\u002FGB within 3-months before signing the Informed Consent Form (ICF), or on the date of the ICF signature according to Trimbow® Summary of Product Characteristics (SmPC)\n* Patients who are willing and able to give their written consent to participate in the study\n\nExclusion Criteria:\n\n\\- Patient known to be participating in any interventional study during the study period and in the 3 months prior to BDP\u002FFF\u002FGB initiation.",{"count":590,"type":21},396,"This multicenter, retrospective-prospective, cohort study aims to evaluate the effectiveness and safety of Extra-fine Beclometasone Diproprionate\u002FFormoterol Fumarate\u002FGlycopyrronium Bromide (EF-BDP\u002FFF\u002FGB) therapy in adults with severe or very severe COPD in Brazil. Around 400 patients will be enrolled across approximately 15 sites. Eligible patients must have started treatment on the day of enrollment or up to three months before enrollment. Data will be collected both retrospectively and prospectively, with baseline information covering up to 12 months before treatment initiation. All assessments will occur during routine medical visits, with follow-up expected at approximately 3 ± 1 month and 6 months ± 2 months. The medication Trimbow® will not be provided as part of the study and must be prescribed and used according to the institution's standard clinical practice, regardless of participation in the study.",[26],[28,594,595,596,597],"Real-world evidence","extra-fine particule","Trimbow","Fixed Triple Therapy","2026-04-14",{"date":600,"type":38},"2026-04-17",{"date":539,"type":38},{"date":578,"type":21},{"name":604,"class":45},"Chiesi Farmaceutica Ltda.",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":136,"maxAge":373,"enrollmentInfo":612,"targetDuration":4,"studyType":57,"phases":614,"briefSummary":615,"conditions":616,"keywords":617,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":4},"100633497","inhaler-training-to-enhance-nurses-competency-in-patient-inhaler-education-100633497","NCT07527455","Inhaler Training to Enhance Nurses' Competency in Patient Inhaler Education","Effectiveness of Theory-based Inhaler Training to Enhance Nurses' Competency in Patient Inhaler Education: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Registered nurses\n* Holding valid practicing certificate issued by the Nursing Council of Hong Kong\n\nExclusion Criteria:\n\n• Unable to speak \\& read Chinese",{"count":613,"type":21},82,[83],"Nurses play a pivotal role in assessing, educating, and regularly reviewing patients' inhaler techniques. However, inadequate knowledge and skills among nurses can hinder their ability to accurately assess patients' inhaler technique or provide effective guidance to those receiving inhaler therapy. This project aims to develop an effective educational tool\u002Fprogram on inhaler education for healthcare workers and nurses.\n\nThis is an assessor-blinded, two-armed randomized controlled trial with a 4-month follow-up. The study will be conducted at a training institute of the Hong Kong Hospital Authority, the Institute of Advanced Nursing Studies. The intervention consists of a theory-based, face-to-face inhaler training workshop grounded in Social Learning Theory. The workshop integrates cognitive aids, hands-on demonstrations, and competency assessments using a standardized checklist. To support ongoing learning, participants will receive follow-up instructional videos and periodic reminders to reinforce and maintain their skills in patient inhaler education.\n\nQuestionnaires will be used to collect participants' demographic information and knowledge and skills regarding inhaler use at baseline, immediate post-training session and 4-month follow-up. Qualitative feedback from trainees will be collected.",[26],[31,28,618,619,620,621],"Inhaler","Randomized controlled trial","Training","Nurse","2026-04-13",{"date":624,"type":38},"2026-04-16",{"date":626,"type":21},"2026-04-09",{"date":628,"type":21},"2027-02-28",{"name":630,"class":102},"Hong Kong Metropolitan University",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":471,"sex":17,"minAge":18,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":642,"conditions":643,"keywords":646,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":650,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":103},"100601572","using-multiomics-to-define-mechanisms-of-rhinovirus-induced-chronic-obstructive-pulmonary-disease-exacerbations-to-develop-novel-therapies-and-therapeutic-targets-100601572","NCT07112235","Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","Using Multiomics to Define Mechanisms of RhinoVirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","MRVCOPD","Inclusion Criteria for COPD subjects\n\n* Male or female sex\n* Age ≥40 years and ≤75 years at the time of signing the consent form\n* Medical history or clinical diagnosis of COPD\n* Significant smoking history, defined as:\n\n  * Cumulative smoking history of at least 20 pack years\n  * Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n* COPD spirometry criteria:\n\n  * Post bronchodilator FEV1 of \\\u003C80% and ≥50% predicted for age and height (equivalent to GOLD criteria stage 2 for 'Moderate' severity COPD9)\n  * Post-bronchodilator FEV1\u002FFVC ratio \\\u003C0.7\n  * β-agonist reversibility: an improvement of less than 12% predicted FEV1 and less than 200mL after 200 micrograms of salbutamol or equivalent short acting beta-2 agonist bronchodilator.\n* History of acute exacerbations of COPD as defined by the participant answering \"yes\" to the question: \"do your COPD symptoms get noticeably worse when you catch a cold?\"\n* Clinically stable with no COPD exacerbations within 8 weeks prior to enrolment\n* Permitted to take short and long-acting bronchodilators including beta agonists and muscarinic antagonist inhalers\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active within 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than COPD, asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy\n\nInclusion Criteria for non-smoking controls\n\n* Male or female sex\n* Age ≥ 40 years and ≤ 75 years at the time of signing the consent form\n* No history or clinical diagnosis of COPD\n* No significant smoking history, defined as:\n\n  * Less than 5 pack year cumulative smoking history\n  * Has not smoked or used e-cigarettes\u002Fvapes in the last 1 year\n* Controls spirometry criteria\n\n  * FEV1 of ≥80% predicted for age and height\n  * FEV1\u002FFVC ratio ≥0.7\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active in the 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy.\n\nInclusion Criteria for smoking controls\n\n• Identical to non-smoking controls, with the exception of smoking history:\n\n* Cumulative smoking history of at least 20 pack years.\n* Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n\nExclusion Criteria:\n\n* Participants with other causes of chronic airflow limitation, including but not limited to:\n\n  * Bronchiectasis including cystic fibrosis\n  * Bronchiolitis obliterans\n  * Carcinoma of the bronchus\n  * Fibrosis such as tuberculosis (TB), idiopathic pulmonary fibrosis\n* Presence of any significant systemic disease, that in the opinion of the investigator would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured.\n\n  * For example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric conditions.\n* Pregnant, planning to become pregnant, testing positive for pregnancy at the screening visit test, or nursing females during and within 30 days of treatment.\n* Treatment with oral, inhaled or nasal corticosteroids within 8 weeks prior to enrolment.\n* Treatment with antibiotics in the 8 weeks preceding enrolment.\n* Treatment with nasal medications, anti-leukotrienes, anti-histamine at the time of the study.\n* Presence (at screening) of serum rhinovirus-A16 neutralising antibodies in a titre \\>1:2.\n* Individuals with close contact to at risk patient group, including:\n\n  * Infants (less than 6 months);\n  * The extremely elderly or infirm;\n  * Pregnant and\u002For breastfeeding women;\n  * Patients with immunosuppression (e.g., human immunodeficiency virus (HIV), transplant recipients on anti-rejection medications, those undergoing chemo- or immuno-therapy).\n  * Other factors that in the opinion of the investigator are considered a risk.\n* Participation in other clinical research studies that, in the opinion of the investigator, would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured in this or other studies, or (c) present an unacceptable visit burden to the participant.","75 Years",{"count":641,"type":21},50,"The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses.\n\nThe main questions the study aims to answer are:\n\n* What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations?\n* Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD?\n\nThe study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.",[26,644,645],"Rhinovirus Infection","Exacerbation of COPD",[28,31,32,647,648,649],"Multiomics","Rhinovirus","Viral challenge study",{"date":598,"type":38},{"date":652,"type":38},"2025-10-08",{"date":654,"type":21},"2027-03-31",{"name":656,"class":102},"Imperial College London",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":17,"minAge":315,"maxAge":665,"enrollmentInfo":666,"targetDuration":4,"studyType":57,"phases":668,"briefSummary":669,"conditions":670,"keywords":671,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":103},"100629073","mobile-health-self-management-intervention-for-patient-with-chronic-obstructive-pulmonary-disease-100629073","NCT07469904","Mobile Health Self-Management Intervention for Patient With Chronic Obstructive Pulmonary Disease","Evaluation of the Effectiveness of a Pharmacist-Led Interactive Mobile Health Intervention (Serious Games) for Improving Health Outcomes in Adults With COPD (Pilot RCT)","AERIS","Inclusion Criteria:\n\n* Adults aged 50 years and older\n* Diagnosed with chronic obstructive pulmonary disease (COPD) and clinically stable at the time of enrollment\n* Receiving inhalation therapy\n* Able to use or access a smartphone\n* Able to communicate in Bahasa Indonesia\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Other respiratory diseases (active tuberculosis, lung cancer, asthma, and pneumonia)\n* Serious comorbidities (renal insufficiency and cardiac failure, terminal illness, life expectancy \\\u003C6 m)\n* mental disorders or cognitive dysfunction\n* auditory, visual, or verbal inability\n* participation in other intervention studies","85 Years",{"count":667,"type":21},126,[83],"This clinical trial aims to evaluate the effectiveness of a pharmacist-led interactive mobile health intervention (serious game) in adults aged 50 years and older with chronic obstructive pulmonary disease (COPD). The study will test whether the intervention improves health status compared with usual care. Secondary outcomes include inhaler technique, medication adherence, health knowledge, dyspnea, clinical events, healthcare utilization, and costs. Participants in the intervention group will receive pharmacist guidance and use the serious game at home for 2 weeks.",[28,26],[663,672],"serious games","2026-03-23",{"date":675,"type":38},"2026-03-27",{"date":677,"type":21},"2026-03-26",{"date":679,"type":21},"2026-07",{"name":681,"class":102},"Universitas Katolik Widya Mandala Surabaya"]